Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

the simple pharma company limited - alprostadil - creme - 300 mikrogram

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

Øresund pharma aps - natriumnitroprussiddihydrat - pulver til infusionsvæske, opløsning - 60 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

sandoz a/s - azacitidin - pulver til injektionsvæske, suspension - 25 mg/ml

Den Europæiske Union - dansk - EMA (European Medicines Agency)

novartis europharm limited - secukinumab - arthritis, psoriatic; psoriasis; spondylitis, ankylosing - immunosuppressiva - plaque psoriasiscosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults and children from the age of 6 years old who are candidates for systemic therapy. hidradenitis suppurativa (hs)cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic hs therapy. psoriasis arthritiscosentyx, alene eller i kombination med methotrexat (mtx), er indiceret til behandling af aktiv psoriasis artrit hos voksne patienter, når svar på tidligere sygdomsmodificerende anti-reumatiske lægemidler (dmard) behandling har været mangelfuld. aksial spondyloarthritis (axspa)ankyloserende spondylitis (som, røntgen aksial spondyloarthritis)cosentyx er indiceret til behandling af aktiv ankyloserende spondylitis i voksne, der har reageret tilstrækkeligt til konventionel behandling. non-radiographic axial spondyloarthritis (nr-axspa)cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence in adults who have responded inadequately to non steroidal anti inflammatory drugs (nsaids). juvenile idiopathic arthritis (jia)enthesitis-related arthritis (era)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. juvenile psoriatic arthritis (jpsa)cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastiske midler - vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with: intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification. vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for hsct with aml with >30% marrow blasts according to the who classification.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

celgene europe bv - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastiske midler - azacitidine celgene is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification,aml with >30% marrow blasts according to the who classification.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

betapharm arzneimittel gmbh - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastiske midler - azacitidine betapharm er indiceret til behandling af voksne patienter, der ikke er berettiget til hæmatopoietisk stamcelle transplantation (hsct) med:intermediær-2 og højrisiko myelodysplastisk syndrom (mds) i henhold til international prognostic scoring system (ipss),kronisk myelomonocytisk leukæmi (cmml) med 10 % til 29 % marv blaster uden myeloproliferative lidelse,akut myeloid leukæmi (aml) med 20 % til 30 % blaster og multi-slægt dysplasi, ifølge world health organization (who) klassifikation,aml med > 30 % marv blaster i henhold til who-klassifikationen.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

mylan ireland limited - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastiske midler - azacitidine mylan is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29% marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30% blasts and multi lineage dysplasia, according to world health organisation (who) classification,aml with > 30% marrow blasts according to the who classification.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

accord healthcare s.l.u. - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastiske midler - azacitidine accord er indiceret til behandling af voksne patienter, der ikke er berettiget til hæmatopoietisk stamcelle transplantation (hsct) med:- intermediær-2 og højrisiko myelodysplastisk syndrom (mds) i henhold til international prognostic scoring system (ipss),- kronisk myelomonocytisk leukæmi (cmml) med 10-29 % marv blaster uden myeloproliferative lidelse,- akut myeloid leukæmi (aml) med 20-30 % blaster og multi-slægt dysplasi, ifølge world health organisation (who) klassifikation,- aml med >30% marv blaster i henhold til who-klassifikationen.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

stada arzneimittel ag - azacitidin - pulver til injektionsvæske, suspension - 25 mg/ml